{"name":"Nectin Therapeutics Ltd","slug":"nectin-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NTX-1088","genericName":"NTX-1088","slug":"ntx-1088","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"NTX-1088","genericName":"NTX-1088","slug":"ntx-1088","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQTnRDOU51V0VmM0xIMmRIcFdnUjJ5MHhZNGszQ1JxOGl3V3pnUEZvNXFBU1hrTnlYMkFxU3B2elFDc1gySWFSSS1FRlFicG03NXJza0JDQllJbjAwRGN1alFSNTdQd0hqdURTZTIyQjFnNklJR0VEbmp0OVV2bTc3OWZqRUVhUFVCMFN3QnFXWWRvclRadlRGYW1icmc4NHZETVEyeWpJZFF4TmNySEtmejFzbFN1UlZiU2Jvdk83TkRHeEtjRXZPY0F1dWFCT0pUXzlTamVXc3laTGE3QTVJeTVtNV8wTnVrYV9IT1UwcjdQUQ?oc=5","date":"2026-03-10","type":"deal","source":"TipRanks","summary":"Corbus Pharmaceuticals: Advancing Best-in-Class Nectin-4 ADC and Emerging Obesity Franchise Support Buy Rating - TipRanks","headline":"Corbus Pharmaceuticals: Advancing Best-in-Class Nectin-4 ADC and Emerging Obesity Franchise Support Buy Rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - Nature","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOQ3FWMUpoaWtZZVVKdzZaeUFtZDdBUEhTY1JDV1pMWXYta2lfYWNmRTd0X2lDVTVPeFl2MHZhazI5NDNWU1pKdDNURGNLcm1Qc2pVQl95MXJUN1BwalE4M3NETHNSMnphbUJDd1ZsRjVwbHRGNjZ4LWlPMVdLLTgwS1FvM1h1N2xsLUlDVU1iYmZucUZsbmJj?oc=5","date":"2026-01-05","type":"pipeline","source":"Fierce Biotech","summary":"Aktis aims for $209M windfall from 1st biotech IPO of 2026 - Fierce Biotech","headline":"Aktis aims for $209M windfall from 1st biotech IPO of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQLXJJSHF4N2FqRGlGUnJtdnNHV1hCZnVoekh0RXRzSVF6WlhHWmhyOFg1dWF1N1pMLURfZmpBZE5ObWpRekktdWJ1RkV2QTctNmE2TmJxMjdtSEh1MXhLMnA1NGZwWjB2cWY5LWFHVjNCNzQ0M3YzRlJSSWFheEFmcHo0UF9Ia0d2d3JNUEFGYjBRZ0N6VlV4eENpbw?oc=5","date":"2025-12-22","type":"trial","source":"Fierce Biotech","summary":"Big Pharma-backed Aktis plans IPO to fund radiopharma trials - Fierce Biotech","headline":"Big Pharma-backed Aktis plans IPO to fund radiopharma trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQQWF4bjBGZURZNXMyM2dVMGl2eURNclVlcUFjbFpxXy1TLV9mb0Myc1lhTFlUVG9lSm1YaEd5bkFSN3dReGtLRkFGaHdWQ3EtQWNYTzJOTnNOSFlSTVE2UVF4LXNab0s2V1ZtVzl4WHBpN2ctY0lQVGhBQUFCb1JtM1IySjFmaDlLQ2ZCYVhfQms5RTIzVXo2RXA4R2plVF9mYlBF?oc=5","date":"2025-11-04","type":"regulatory","source":"Oncology News Central","summary":"Oncology Drugs Fast-Tracked by the FDA in October 2025 - Oncology News Central","headline":"Oncology Drugs Fast-Tracked by the FDA in October 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQc3pLOEJjQVpNTTZTdFpJbjh3d1JKb1R0WkFWazU4NTVkQVctNW9hYTUxMGplaHRjTkphcVV1T0NEakNtNjhHbGJhQ2FNcU02SDZscHF4bUNLTHJCLXVrNjdvUW96YnlhOFBZYTNNQXlhSGJRT250QTRGbUZybGRsOEZfVXR3bS10V0hLUXFranR1S3JaQnFMTmsyTjV1RG9tTVpRMFN3SUsyUTZBWDNZZTRNWGFlRmxLSmM1ak9yRk1QMHZDMS1SN1FYZnFTNkNFWmZOdlVpRFJnblZfUEN6U2s0ZHJJQQ?oc=5","date":"2025-10-30","type":"earnings","source":"Business Wire","summary":"Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Business Wire","headline":"Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNRkhFMHplRGVGVmcwbDhNN1N6cWhkUUpzNEpQVThLZGxGbGJHS2gwNUN4cTNIQXoybzRDcmVfcVRuQ0JWRWpQWGlEdEM2aFJUbHh2OGgwdmdhOTZ6aVVIcG1fbHNsVlNUamtvbm9qQVdDaEpJUU53a0JWcjBQRjU2Z3VCTkp1Wlo4X2FTM3RkbkRPVnMyelA5YTJUNnVpcHFQOGtKYndBbFp1dUM2OTUtbEkxWS1iMUFidk5IZFBfX09hMzN1RWlRc183ZlZNYnNFMXRRb1dkM0E1bno4SG1Ha2FxeWFkRTY1Q3BtNkpvdEJYdXBxbWtyNTNmM3dvQVpZZmpIdUFlYm8?oc=5","date":"2025-10-18","type":"pipeline","source":"GlobeNewswire","summary":"Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 - GlobeNewswire","headline":"Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNMVZWX3hJcmpEZzRhbW56YTVzMktiZGhoWnEtNTlxRUdWVUxKampVR2hQQnJtVWNvRjJmSkpQdndxLUdfYWlvb20zSWZranFhdTlLdlRHQWhGYV9iODg0UlZ1VVJXR05XNzVvWEU3WUJZSFFsUGo1U1NsZFZ6UEl4UmlabzUxNEZEdS1RbE0zalZHWmRDYjhQbFR3YWhhVTNBVGJhYXc0MXB2MVVyWUt4WVQ3bHUweV8wYTRnZTB6MWp1QmxjYjdIYjEtNjZ0cV9PM2JwVy15dzVqdlNWSkxaOUpPT2JfcG5kMlR6UWRacENta0U3Q19WZEZsZlhqOE5raFhRVFlWTlBzTW5Mc1ZQRVFyZEF6bmFMVy13dXVNckZqNFhTNFBZ?oc=5","date":"2025-10-15","type":"pipeline","source":"PR Newswire","summary":"Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 - PR Newswire","headline":"Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Pl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1wY04wUHpRWFVrTnBfOVBoSnVjTkRxMUhQT056dnR2bkhwNWhJaGk0a0ViZ1M1anFXT0pSY0lLNXItc0FWS1RIMkpuc1RxUlFJSkJpS2pyY19SaVhJaHlMallkeGRscU1lOE1N?oc=5","date":"2025-02-13","type":"trial","source":"Wiley Online Library","summary":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma - Wiley Online Library","headline":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOeXh4VGs1Z0c2dFA5ZklaZU5XQk5WbDM5Z3NrUUZGZFpjXzUzTmJrWHJOT1ZQY3BfX3IyMGF1X1drWnY0cF8xc1Q2RE1oTUxlR3YxSnc0dlgyMzhnSVB4aDRkeHZCWDVreGwyVnIwdmdUa2tGWTNkdEttazFFVVM1M3FVNkVKb2ZBb3o2ejRScWltQXhnQnA1dmdUbGtPdw?oc=5","date":"2025-01-27","type":"trial","source":"Clinical Trials Arena","summary":"Innate Pharma doses first patient in Nectin-4 ADC trial - Clinical Trials Arena","headline":"Innate Pharma doses first patient in Nectin-4 ADC trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZzVsY3ZZSEtKWXNrWjNVZUxQZjU2VV9uOVVaZlhJUVpRWmo5NGNHRXdJZ3oxSHRqS0pRQk9XMEtJRGY0WHEyM0N6a0ZFRGprQmRjd2NkaWI1VUJJQk5HLWc2UVVPZkluZWlPNTlTYlN6Tm16WlYwVjBoYUZFaHMtaUV3dVQtMWl0VS1SU2ZR?oc=5","date":"2024-05-06","type":"pipeline","source":"Contract Pharma","summary":"GIBF Invests $10M in Nectin Therapeutics - Contract Pharma","headline":"GIBF Invests $10M in Nectin Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPSnZxclBCTW1qMnd0clJvMW8yYk9fRUZfVmp5LWJXbWRrbUM1bW5RaHFfQXBNMF8xalNrUHh1clhzc2Fxc3dDNFF3eGx4bndvNDlhUHJDcjhpQTRsSWJwcjJGbEx2LWpkTFhCZjBqSjJmQ3IyNnNycDVDWjdLVFBKYXlWa3pON293bFFkWUs3WEFPZkVJRThTN1RSSnBreF80Zlp0S1FoY011OUg5UTU4VWFkcm0yS2c?oc=5","date":"2023-03-27","type":"pipeline","source":"TechTarget","summary":"Nectin Therapeutics Collaborates with Merck on Cancer Treatment - TechTarget","headline":"Nectin Therapeutics Collaborates with Merck on Cancer Treatment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}